1.
Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions
by Wong, Benjamin C Y
Gut, 2012, Vol.61 (6), p.812-818
2.
Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial
by Walter, I
Medical oncology (Northwood, London, England), 2017, Vol.34 (12), p.192-10
3.
The effect of selective serotonin reuptake inhibitor (SSRI) on pain-related behavior in a rat model of neuropathic pain
by Saito, Hiroharu
European spine journal, 2014, Vol.23 (11), p.2401-2409
4.
Pharmacokinetic, Pharmacodynamic, and Safety/Tolerability Profiles of CG100649, a Novel COX-2 Inhibitor: Results of a Phase I, Randomized, Multiple-dose Study in Healthy Korean Men...
by Kim, Mi Jo, MD
Clinical therapeutics, 2015, Vol.37 (1), p.197-210
5.
Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy
by Maiden, Laurence
Journal of gastroenterology, 2009, Vol.44 (Suppl 19), p.64-71
6.
Effects of Ketoconazole on the Pharmacokinetic Properties of CG100649, A Novel NSAID: A Randomized, Open-Label Crossover Study in Healthy Korean Male Volunteers
by Choi, Hee Youn, MD
Clinical therapeutics, 2014, Vol.36 (1), p.115-125
7.
NSAIDs and colorectal cancer prevention
by Iwama, Takeo
Journal of gastroenterology, 2009, Vol.44 (Suppl 19), p.72-76
8.
Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma
by Toomey, Deirdre
Vaccine, 2008, Vol.26 (27), p.3540-3549
9.
Tumor-associated macrophages promote lung metastasis and induce epithelial-mesenchymal transition in osteosarcoma by activating the COX-2/STAT3 axis
by Han, Yu
Cancer letters, 2018, Vol.440-441, p.116
10.
COX-1 and COX-2 inhibitors
by Hawkey, C.J
Baillière's best practice & research. Clinical gastroenterology, 2001, Vol.15 (5), p.801-820
11.
Comparison of Different Loading Dose of Celecoxib on Postoperative Anti-inflammation and Analgesia in Patients Undergoing Endoscopic Nasal Surgery-200 mg Is Equivalent to 400 mg...
by Zhao, Hong
Pain medicine (Malden, Mass.), 2011, Vol.12 (8), p.1267-1275
12.
Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: A retrospective study of physician-patient pairs in Taiwan
by Hsiao, Fei-Yuan, PhD
Clinical therapeutics, 2009, Vol.31 (11), p.2618-2627
13.
COX-2-derived PGE.sub.2 triggers hyperplastic renin expression and hyperreninemia in aldosterone synthase-deficient mice
by Karger, Christian
Pflügers Archiv, 2018, Vol.470 (7), p.1127
14.
Periodontal Disease, Tooth Loss, and Cancer Risk
by Michaud, Dominique S
Epidemiologic reviews, 2017, Vol.39 (1), p.49-58
15.
Targeting ER stress induced apoptosis and inflammation in cancer
by Verfaillie, Tom
Cancer letters, 2010, Vol.332 (2), p.249-264
16.
Beneficial action of resveratrol: How and why?
by Diaz-Gerevini, Gustavo Tomas, Ph.D
Nutrition (Burbank, Los Angeles County, Calif.), 2016, Vol.32 (2), p.174-178
17.
Rofecoxib, a COX-2 Inhibitor, Lowers C-Reactive Protein and Interleukin-6 Levels in Patients With Acute Coronary Syndromes
by Monakier, Daniel
Chest, 2004, Vol.125 (5), p.1610-1615
18.
19.
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement
by Cuzick, Jack, Prof
The lancet oncology, 2009, Vol.10 (5), p.501-507
20.
